Regarding safety, some cytokine release syndrome (CRS) was observed, typically early and mostly grade 1 or 2, and manageable with standard mitigation strategies. No new safety signals were identified beyond what was previously known. Overall, this shows a high and durable response rate in previously treated patients, with mostly low-grade CRS that is manageable—highlighting a promising chemo-free, immunotherapy-based regimen for relapsed/refractory follicular lymphoma.
Pharmacy Times: How does the mechanism of action of epcoritamab as a bispecific T-cell engager differ from traditional therapies used in follicular lymphoma?
Mahmoudjafari: Epcoritamab is unique. It's considered chemotherapy-free. It’s a CD3xCD20 bispecific T-cell engager that simultaneously binds CD20 on malignant B cells and CD3 on T cells. Essentially, it redirects a patient’s own T cells to directly kill the lymphoma cells. This differs fundamentally from traditional follicular lymphoma therapies, which rely on passive immune mechanisms or cytotoxic chemotherapy. Compared with lenalidomide alone, epcoritamab provides more direct, targeted action, leading to potent, antigen-specific cytotoxicity without the ex vivo cell manipulation required for CAR T-cell therapy. So it’s a unique mechanism of action and clearly shows strong responses in this patient population.
Pharmacy Times: Following the FDA’s approval, where does the epcoritamab plus rituximab and lenalidomide regimen fit within the current treatment paradigm for relapsed/refractory FL?
Mahmoudjafari: This was recently approved in November 2025 by the FDA in combination with rituximab and lenalidomide for adult patients with relapsed/refractory follicular lymphoma after at least 1 prior systemic therapy. In terms of landscape implications, this is the first bispecific antibody combination regimen in a randomized phase 3 trial to demonstrate superior outcomes versus standard R². The magnitude of progression-free survival advantage, deep complete response rates, and durability suggest this could become a new benchmark in second-line therapy. It’s an important early option for patients who have progressed after frontline immunochemotherapy and are candidates for an immune-based outpatient regimen.
It may be particularly attractive for patients looking to avoid chemotherapy-related toxicities, those who aren’t ideal candidates for CAR T-cell therapy, or those who prefer a readily available off-the-shelf option with strong efficacy. The challenge isn’t with epcoritamab itself, but lenalidomide can be toxic, so pharmacists need to be mindful of management considerations for these patients.
Pharmacy Times: What practical considerations should pharmacists keep in mind when helping clinicians and patients implement this regimen in practice?
Mahmoudjafari: Pharmacists play a central role in implementing any new FDA-approved regimen, especially bispecific antibodies. Pharmacists must coordinate to ensure patients receive their step-up dosing, whether inpatient, outpatient, or a combination. They also ensure the care team follows mitigation protocols. Often pharmacists help create these protocols and make sure adherence is maintained while educating patients and caregivers. Pharmacists are critical in selecting premedications and managing prophylaxis, particularly because this regimen can be immunosuppressive. Patients often require prophylactic antibiotics, and pharmacists help monitor and prevent infections.
With lenalidomide, cytopenias are common, so pharmacists manage these and other immune-mediated toxicities. Pharmacists also support financial navigation, helping patients afford therapy and get insurance approval. In short, pharmacists have key operational, clinical, and financial responsibilities in implementing this regimen safely and effectively.
Pharmacy Times: From a patient perspective, what improvements does this approval offer compared with existing standard options in terms of outcomes and quality of life?
Mahmoudjafari: From a patient perspective, this approval offers high response rates without traditional chemotherapy, which some patients are hesitant to pursue. It’s convenient and off-the-shelf, so patients don’t have to worry about cell collection and manufacturing over several weeks. Patients also avoid prolonged hospitalizations often seen with CAR T-cell therapy. There’s potential for improved quality of life, as many patients can maintain daily activities and work while receiving outpatient treatment. Overall, this regimen allows faster access to effective therapy at the first relapse.
Pharmacy Times: How do you think the approval of a bispecific antibody combination will influence future therapeutic development in follicular lymphoma or other indolent lymphomas?
Mahmoudjafari: This approval validates bispecific antibodies as a cornerstone platform in indolent lymphomas and beyond. Many bispecifics are being studied in hematologic malignancies and other areas of oncology. We can anticipate accelerated development of combination strategies, movement into earlier lines of therapy, and continued exploration to maximize efficacy. The focus remains on chemo-free, immune-based regimens that are scalable and accessible to the broader community.